FilingSEC EDGAR8-K
Immuneering Reports Q3 2026 Financial Results and Updates Clinical Trial Progress
· SEC accepted
Stageongoing
Filing content
The company reported a net loss of $24.2 million for the third quarter of 2026 and announced the extension of its Phase 2 pancreatic cancer trial and accelerated enrollment for its Phase 3 MAPKeeper 301 trial.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…